Edwards Lifesciences Corp (EW): who owns it and who trades it
As of Nov 16, 2026, EW insiders reported 55 open-market sales worth $34.1M and no purchases in the last 12 months, with 61% of the sale value made under pre-set 10b5-1 plans. The largest seller was Donald E Bobo Jr (CVP), with $16.2M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Edwards Lifesciences
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EW
1,326 funds and institutions reported EW shares worth $47.6B at the end of Q2 2026, about 92% of the company. The largest holder is BlackRock, Inc. with 10.2%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 58.79M | 10.21% | $5.3B | +12% |
| Vanguard Capital Management LLC | 37.62M | 6.53% | $3.4B | -0% |
| Vanguard Portfolio Management LLC | 26.41M | 4.59% | $2.4B | No change |
| State Street Corp | 26.32M | 4.57% | $2.4B | +0% |
| JPMorgan Chase & Co | 22.78M | 3.96% | $2.1B | – |
| Wellington Management Group LLP | 16.83M | 2.92% | $1.5B | -24% |
| Geode Capital Management, LLC | 15.44M | 2.68% | $1.4B | +18% |
| Bank of New York Mellon Corp | 14.08M | 2.45% | $1.3B | -16% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 13.00M | 2.26% | $1.2B | +1% |
| Ninety One UK Ltd | 12.34M | 2.14% | $1.1B | -0% |
| Aristotle Capital Management, LLC | 8.67M | 1.50% | $784M | – |
| Alliancebernstein L.P. | 8.66M | 1.50% | $694M | +150% |
| FMR LLC (Fidelity) | 8.44M | 1.47% | $763M | -42% |
| Norges Bank | 8.37M | 1.45% | $757M | – |
| Brown Advisory Inc | 7.37M | 1.28% | $666M | +5% |
| Bank of America Corp | 6.69M | 1.16% | $605M | +72% |
| Artisan Partners Limited Partnership | 6.63M | 1.15% | $599M | +27% |
| Morgan Stanley | 6.34M | 1.10% | $573M | -10% |
| Deutsche Bank Ag\ | 5.71M | 0.99% | $517M | -6% |
| Arrowstreet Capital, Limited Partnership | 5.68M | 0.99% | $514M | +200% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EW insiders reported $0 of open-market purchases and $34.1M of sales. 61% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Daniel J. Lippis | CVP | Sale plan | 619 | $104.25 | $64.5K | Form 4 |
| Nov 9, 2026 | Donald E Bobo Jr | CVP | Sale plan | 48,900 | $103.05 | $5M | Form 4 |
| Nov 9, 2026 | Bernard J Zovighian | CEO | Sale plan | 9,184 | $103.39 | $949K | Form 4 |
| Nov 9, 2026 | Bernard J Zovighian | CEO | Sale plan | 13,916 | $102.78 | $1.4M | Form 4 |
| Oct 8, 2026 | Daniel J. Lippis | CVP | Sale plan | 619 | $85.65 | $53K | Form 4 |
| Sep 11, 2026 | Daniel J. Lippis | CVP | Sale plan | 619 | $87.51 | $54.2K | Form 4 |
| Aug 31, 2026 | Andrew M. Dahl | Vice president | Sale | 544 | $91.06 | $49.5K | Form 4 |
| Aug 28, 2026 | Annette Bruls | CVP | Sale | 2,644 | $89.98 | $238K | Form 4 |
| Aug 26, 2026 | Daveen Chopra | CVP | Sale | 30,646 | $90.99 | $2.8M | Form 4 |
| Aug 26, 2026 | Daveen Chopra | CVP | Sale | 1,154 | $91.76 | $106K | Form 4 |
| Aug 26, 2026 | Wayne Markowitz | CVP | Sale | 1,240 | $91.47 | $113K | Form 4 |
| Aug 11, 2026 | Daniel J. Lippis | CVP | Sale plan | 619 | $92.03 | $57K | Form 4 |
| Jul 30, 2026 | Wayne Markowitz | CVP | Sale | 146 | $86.03 | $12.6K | Form 4 |
| Jul 28, 2026 | Wayne Markowitz | CVP | Sale | 9,628 | $85.06 | $819K | Form 4 |
| Jul 27, 2026 | Bernard J Zovighian | CEO | Sale | 2,921 | $83.93 | $245K | Form 4 |
| Jul 10, 2026 | Daniel J. Lippis | CVP | Sale plan | 619 | $91.70 | $56.8K | Form 4 |
| Jun 30, 2026 | Daniel J. Lippis | CVP | Sale plan | 619 | $91.40 | $56.6K | Form 4 |
| Jun 17, 2026 | Bernard J Zovighian | CEO | Sale plan | 523 | $87.92 | $46K | Form 4 |
| May 29, 2026 | Andrew M. Dahl | Vice president | Sale | 568 | $86.08 | $48.9K | Form 4 |
| May 27, 2026 | Donald E Bobo Jr | CVP | Sale | 23,145 | $86.42 | $2M | Form 4 |
| May 22, 2026 | Daveen Chopra | CVP | Sale | 1,500 | $84.60 | $127K | Form 4 |
| May 18, 2026 | Daniel J. Lippis | CVP | Sale plan | 620 | $81.14 | $50.3K | Form 4 |
| May 15, 2026 | Donald E Bobo Jr | CVP | Sale | 8,000 | $81.82 | $655K | Form 4 |
| May 15, 2026 | Donald E Bobo Jr | CVP | Sale | 9,968 | $82.07 | $818K | Form 4 |
| May 12, 2026 | Bernard J Zovighian | CEO | Sale plan | 35,506 | $77.92 | $2.8M | Form 4 |
| May 12, 2026 | Bernard J Zovighian | CEO | Sale plan | 845 | $78.40 | $66.2K | Form 4 |
| May 11, 2026 | Wayne Markowitz | CVP | Sale | 593 | $79.73 | $47.3K | Form 4 |
| May 4, 2026 | Daniel J. Lippis | CVP | Sale plan | 1,019 | $83.98 | $85.6K | Form 4 |
| May 1, 2026 | Daniel J. Lippis | CVP | Sale plan | 19 | $83.99 | $1.6K | Form 4 |
| May 1, 2026 | Daniel J. Lippis | CVP | Sale plan | 1,000 | $82.99 | $83K | Form 4 |
| Apr 9, 2026 | Scott B. Ullem | CFO | Sale plan | 8,324 | $79.79 | $664K | Form 4 |
| Apr 9, 2026 | Scott B. Ullem | CFO | Sale plan | 4,676 | $80.50 | $376K | Form 4 |
| Apr 6, 2026 | Daniel J. Lippis | CVP | Sale plan | 1,019 | $80.98 | $82.5K | Form 4 |
| Apr 2, 2026 | Donald E Bobo Jr | CVP | Sale plan | 4,676 | $80.59 | $377K | Form 4 |
| Apr 2, 2026 | Donald E Bobo Jr | CVP | Sale plan | 18,004 | $80.05 | $1.4M | Form 4 |
| Mar 11, 2026 | Scott B. Ullem | CFO | Sale plan | 7,901 | $85.21 | $673K | Form 4 |
| Mar 11, 2026 | Scott B. Ullem | CFO | Sale plan | 5,099 | $84.46 | $431K | Form 4 |
| Mar 11, 2026 | Daniel J. Lippis | CVP | Sale plan | 1,019 | $85.38 | $87K | Form 4 |
| Mar 2, 2026 | Donald E Bobo Jr | CVP | Sale plan | 11,340 | $85.93 | $974K | Form 4 |
| Feb 25, 2026 | Donald E Bobo Jr | CVP | Sale | 24,000 | $83.84 | $2M | Form 4 |
| Feb 12, 2026 | Bernard J Zovighian | CEO | Sale | 19,898 | $76.61 | $1.5M | Form 4 |
| Feb 12, 2026 | Bernard J Zovighian | CEO | Sale | 2,532 | $77.13 | $195K | Form 4 |
| Jan 9, 2026 | Daniel J. Lippis | CVP | Sale plan | 1,019 | $85.70 | $87.3K | Form 4 |
| Jan 6, 2026 | Donald E Bobo Jr | CVP | Sale plan | 2,632 | $84.62 | $223K | Form 4 |
| Jan 6, 2026 | Donald E Bobo Jr | CVP | Sale plan | 8,708 | $85.98 | $749K | Form 4 |
| Dec 12, 2025 | Donald E Bobo Jr | CVP | Sale | 5,900 | $83.74 | $494K | Form 4 |
| Dec 12, 2025 | Donald E Bobo Jr | CVP | Sale | 5,486 | $83.79 | $460K | Form 4 |
| Dec 12, 2025 | Daniel J. Lippis | CVP | Sale plan | 1,019 | $84.03 | $85.6K | Form 4 |
| Dec 12, 2025 | Heisz Leslie Stone | Director | Sale | 2,615 | $83.41 | $218K | Form 4 |
| Dec 11, 2025 | Daveen Chopra | CVP | Sale | 2,000 | $84.38 | $169K | Form 4 |
| Dec 10, 2025 | Donald E Bobo Jr | CVP | Sale plan | 11,340 | $83.83 | $951K | Form 4 |
| Dec 10, 2025 | Bernard J Zovighian | CEO | Sale plan | 3,863 | $83.45 | $322K | Form 4 |
| Dec 9, 2025 | Scott B. Ullem | CFO | Sale plan | 7,700 | $84.47 | $650K | Form 4 |
| Dec 8, 2025 | Bernard J Zovighian | CEO | Sale plan | 21,487 | $85.21 | $1.8M | Form 4 |
| Dec 8, 2025 | Wayne Markowitz | CVP | Sale | 583 | $86.01 | $50.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Donald E Bobo Jr | CVP,Strategy/Corp Development | – | $16.2M | Nov 9, 2026 |
| Bernard J Zovighian | CEO, Director | – | $9.4M | Nov 9, 2026 |
| Daveen Chopra | CVP, TMTT & Surgical | – | $3.2M | Aug 26, 2026 |
| Scott B. Ullem | CVP, Chief Financial Officer | – | $2.8M | Apr 9, 2026 |
| Wayne Markowitz | CVP, JAPAC | – | $1M | Aug 26, 2026 |
| Daniel J. Lippis | CVP, JAPAC | – | $905K | Nov 10, 2026 |
| Annette Bruls | CVP, EMEACLA | – | $238K | Aug 28, 2026 |
| Heisz Leslie Stone | Director | – | $218K | Dec 12, 2025 |
| Andrew M. Dahl | SVP, Corporate Controller | – | $98.4K | Aug 31, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EW short interest
Low short interest. 1.6% of EW shares are sold short: about 1 share in 61. Over the last 12 reports the number of shares short went down 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.38M EW shares were sold short, 1.6% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 3.35M shares, buying them all back would take about 2.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.38M | 1.63% | +1% | 3.35M | 2.8 |
| Oct 15, 2026 | 9.33M | 1.62% | -2% | 3.80M | 2.5 |
| Sep 30, 2026 | 9.54M | 1.65% | +5% | 3.88M | 2.5 |
| Sep 15, 2026 | 9.09M | 1.58% | +1% | 2.88M | 3.1 |
| Aug 31, 2026 | 9.02M | 1.57% | -12% | 2.81M | 3.2 |
| Aug 14, 2026 | 10.24M | 1.78% | +2% | 3.26M | 3.1 |
| Jul 31, 2026 | 10.04M | 1.74% | -12% | 5.68M | 1.8 |
| Jul 15, 2026 | 11.35M | 1.97% | -1% | 4.52M | 2.5 |
| Jun 30, 2026 | 11.47M | 1.99% | -3% | 5.44M | 2.1 |
| Jun 15, 2026 | 11.80M | 2.05% | -3% | 4.91M | 2.4 |
| May 29, 2026 | 12.16M | 2.11% | +7% | 5.24M | 2.3 |
| May 15, 2026 | 11.39M | 1.98% | +8% | 4.48M | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded EW
Since Nov 17, 2024, 5 members of Congress reported 4 purchases and 3 sales of EW. The latest was a purchase by Alan Armstrong on Mar 27, 2026, reported Jul 21, 2026.
Purchases 4Sales 3
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Nov 19, 2025 | Josh Gottheimer (D-NJ) | Sale | $1K–$15K | Joint | Dec 29, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $50K–$100K | Self | Jun 22, 2025 | Report |
| Apr 21, 2025 | Bruce Westerman (R-AR) | Sale | $1K–$15K | Self | May 12, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | May 8, 2025 | Report |
| Apr 7, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | May 8, 2025 | Report |
| Mar 3, 2025 | Bruce Westerman (R-AR) | Purchase | $1K–$15K | Self | Apr 16, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Edwards Lifesciences company events
Edwards Lifesciences filed 8 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 28, 2026LeadershipThe Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation, has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. Filing
- Jul 23, 2026ResultsReleased financial results. Filing
- May 8, 2026LeadershipApproval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders of Edwards Lifesciences Corporation, a Delaware Corporation, the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive… Filing
- May 4, 2026LeadershipEdwards Lifesciences Corporation, a Delaware corporation, announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position. Filing
- Apr 23, 2026ResultsReleased financial results. Filing
- Feb 10, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Edwards Lifesciences financials
Famous investors that hold EW
7 of the 50 well-known investors we track reported holding EW in their latest 13F filing. The largest position is Israel Englander's, worth $504M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 5.84M | $504M | 0.4% | +63% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.40M | $207M | 0.1% | -40% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 899,485 | $77.6M | 0.1% | -49% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 408,072 | $35.2M | 0.2% | +48% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 104,900 | $9.1M | 0.0% | +400% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 80,503 | $6.9M | 0.0% | -8% |
| Jeremy Grantham · GMO | Q3 2026 | 20,664 | $1.8M | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Edwards Lifesciences Corp (EW) stock
Who owns the most EW stock?
The largest reported owner of Edwards Lifesciences Corp (EW) is BlackRock, Inc., with 10.2% of the company. In total, 1,326 funds and institutions reported holding EW at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are EW insiders buying or selling?
In the last 12 months, EW insiders reported no open-market purchases and 55 sales worth $34.1M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in EW?
As of Oct 30, 2026, 9.38M EW shares were sold short, 1.6% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 3.35M shares, buying them all back would take about 2.8 trading days (days to cover). See the history.
Have members of Congress traded EW?
Yes. 5 members of Congress reported 4 purchases and 3 sales of EW since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.
Which famous investors hold EW?
7 of the 50 well-known investors we track reported EW in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $504M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.